Back to Search
Start Over
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
- Source :
-
Atherosclerosis [Atherosclerosis] 2024 Jun; Vol. 393, pp. 117516. Date of Electronic Publication: 2024 Mar 16. - Publication Year :
- 2024
-
Abstract
- Aim: We aimed to describe clinical and genetic characteristics, lipid-lowering treatment and atherosclerotic cardiovascular disease (ASCVD) outcomes over a long-term follow-up in homozygous familial hypercholesterolemia (HoFH).<br />Methods: SAFEHEART (Spanish Familial Hypercholesterolaemia Cohort Study) is a long-term study in molecularly diagnosed FH. Data analyzed in HoFH were prospectively obtained from 2004 until 2022. ASCVD events, lipid profile and lipid-lowering treatment were determined.<br />Results: Thirty-nine HoFH patients were analyzed. The mean age was 42 ± 20 years and nineteen (49%) were women. Median follow-up was 11 years (IQR 6,18). Median age at genetic diagnosis was 24 years (IQR 8,42). At enrolment, 33% had ASCVD and 18% had aortic valve disease. Patients with new ASCVD events and aortic valve disease at follow-up were six (15%), and one (3%), respectively. Median untreated LDL-C levels were 555 mg/dL (IQ 413,800), and median LDL-C levels at last follow-up was 122 mg/dL (IQR 91,172). Most patients (92%) were on high intensity statins and ezetimibe, 28% with PCSK9i, 26% with lomitapide, and 23% with lipoprotein-apheresis. Fourteen patients (36%) attained an LDL-C level below 100 mg/dL, and 10% attained an LDL-C below 70 mg/dL in secondary prevention. Patients with null/null variants were youngers, had higher untreated LDL-C and had the first ASCVD event earlier. Free-event survival is longer in patients with defective variant compared with those patients with at least one null variant (p=0.02).<br />Conclusions: HoFH is a severe life threating disease with a high genetic and phenotypic variability. The improvement in lipid-lowering treatment and LDL-C levels have contributed to reduce ASCVD events.<br />Competing Interests: Declaration of competing interest RA reports personal fees and non-financial support from Tecnofarma Chile, NovoNordisk Chile, and personal fees from Novartis Chile, Amgen Spain, and Teva Chile, outside the submitted work. JLDD received honoraria for research activities from Merck Sharp and Dhome Spain, Amgen Spain, and Sanofi Spain. PM, received research grants from Amgen USA and Sanofi Spain.<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
Female
Male
Adult
Follow-Up Studies
Middle Aged
Treatment Outcome
Prospective Studies
Young Adult
Spain epidemiology
Time Factors
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Biomarkers blood
Phenotype
Proprotein Convertase 9 genetics
Proprotein Convertase 9 metabolism
Ezetimibe therapeutic use
Hyperlipoproteinemia Type II genetics
Hyperlipoproteinemia Type II drug therapy
Hyperlipoproteinemia Type II blood
Hyperlipoproteinemia Type II complications
Cholesterol, LDL blood
Homozygote
Anticholesteremic Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1879-1484
- Volume :
- 393
- Database :
- MEDLINE
- Journal :
- Atherosclerosis
- Publication Type :
- Academic Journal
- Accession number :
- 38523000
- Full Text :
- https://doi.org/10.1016/j.atherosclerosis.2024.117516